請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/83354完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 王俊傑(Chun-Chieh Wang) | |
| dc.contributor.author | Hsuan-Chih Chen | en |
| dc.contributor.author | 陳璿之 | zh_TW |
| dc.date.accessioned | 2023-03-19T21:05:26Z | - |
| dc.date.copyright | 2022-09-26 | |
| dc.date.issued | 2022 | |
| dc.date.submitted | 2022-09-21 | |
| dc.identifier.citation | 國家教育研究院（2012）。專利分析名詞解釋。檢自：https://terms.naer.edu.tw/detail/1678926/ Agarwal, S., Desai, S., Holcomb, M. M., & Oberoi, A. (2001). Unlocking the value in big pharma. The McKinsey Quarterly, 1(2), 64. Bae, J., P. (1997). Drug patent expirations and the speed of generic entry. Health services research, 32(1), 87. Bhat, N.V. (2005). Patent term extension strategies in the pharmaceutical industry. Pharmaceuticals Policy and Law, 6(1), 109-122. Bouchard, R. A., Hawkins, R. W., Clark, R., & Hagtvedt, R. (2010). Empirical analysis of drug approval-drug patenting linkage for high value pharmaceuticals. Northwestern Journal of Technology and Intellectual Property, 8(2), 174-227. Chandler, K. (2019). Patents and the pharmaceutical industry: Curbing the abusive practices employed by blockbuster drug companies to prolong market exclusivity. Cornell Journal of Law and Public Policy, 29(2), 467-490. Dayton, C. M., & Schafer, W. D. (1973). Extended tables of t and chi square for Bonferroni tests with unequal error allocation. Journal of the American Statistical Association, 68(341), 78-83. Dwivedi, G., Hallihosur, S., & Rangan, L. (2010). Evergreening: A deceptive device in patent rights. Technology in Society, 32, 324-330. Elizabeth, S. W., & Scott, D. D. (2003). The Hatch-Waxman Act: History, structure, and legacy. Antitrust Law Journal, 71(2), 585-608. Ellery, T., & Hansen, N. (2012). Pharmaceutical lifecycle management: Making the most of each and every brand. (p. 33). New Jersey, USA: John Wiley & Sons, Inc. Feldman, R. (2018). May your drug price be evergreen. Journal of Law and the Biosciences, 5(3), 590-647. Gautam, A., & Pan, X. (2016). The changing model of big pharma: Impact of key trends. Drug discovery today, 21(3), 379-384. Grabowski, H., Long, G., Mortimer, R., & Boyo, A. (2016). Updated trends in US brand-name and generic drug competition. Journal of Medical Economics, 19(9), 836-844. Hemphill, C. S., & Sampat, B. N. (2012). Evergreening, patent challenges, and effective market life in pharmaceuticals. Journal of Health Economics. 31(2), 327-339. Holman, C. M. (2016). In Defense of Secondary Pharmaceutical Patents: A Response to the UN's Guidelines for Pharmaceutical Patent Examination. Indiana Law Review, 50, 759. Hu, Y., Bian, Y., & Wang, Y. (2008). Opening the black box of pharmaceutical patent value: An empirical analysis. Drug Information Journal, 42(6), 561-568. Hutchins, M. (2003). Extending the monopoly – How“secondary patents” can be used to delay or prevent generic competition upon expiry of the basic product patent. Journal of Generic Medicines, 1(1), 57-71. Karshtedt, D.(2019).The more things change: Improvement patents, drug modifications, and the FDA. Iowa Law Review, 104(3), 1129-122. Kesselheim, A. S., Sinha, M. S., & Avorn, J. (2017). Determinants of market exclusivity for prescription drugs in the United States. JAMA internal medicine, 177(11), 1658-1664. Khanna, I. (2012). Drug discovery in pharmaceutical industry: Productivity challenges and trends. Drug discovery today, 17(19-20), 1088-1102. Kim, H. Y. (2017). Statistical notes for clinical researchers: Chi-squared test and Fisher's exact test. Restorative dentistry & endodontics, 42(2), 152-155. Kvesic, Z., D. (2008). Product lifecycle management: Marketing strategies for the Pharmaceutical Industry. Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing, 8(4), 293-301. Kyle, M., K. (2016). Competition law, intellectual property, and the pharmaceutical sector. Antitrust Law Journal, 81(1), 1-36. Kyle, M. K. (2020). The alignment of innovation policy and social welfare: Evidence from pharmaceuticals. Innovation Policy and the Economy, 20(1), 95-123. Lexchin, J. (2017). Market exclusivity time for top selling originator drugs in Canada: A cohort study. Value in Health, 20(8), 1139-1142. Newbert, S. L. (2008). Value, rareness, competitive advantage, and performance: A conceptual-level empirical investigation of the resource-based view of the firm. Strategic Management Journal, 29(7), 745-768. Molina-Carballo, A., Checa-Ros, A., & Mu?oz-Hoyos, A. (2016). Treatments and compositions for attention deficit hyperactivity disorder: A patent review. Expert Opinion on Therapeutic Patents, 26(7), 799-814. Oliveira, R. A. D., & Fierro, I. M. (2018). New strategies for patenting biological medicines used in rheumatoid arthritis treatment. Expert Opinion on Therapeutic Patents, 28(8), 635-646. Olk, P., & West, J. (2020). The relationship of industry structure to open innovation: Cooperative value creation in pharmaceutical consortia. R&D Management, 50(1), 116-135. PharmaCompass(2019). PharmaCompass compilation of Top drugs and pharma companies by sales in 2019. Retrieved from: https://www.pharmacompass.com/data-compilation/top-drugs-by-sales-in-2019-who-sold-the-blockbuster-drugs PharmaCompass (2020). PharmaCompass compilation of top drugs and pharma companies by sales in 2020. Retrieved from: https://www.pharmacompass.com/data-compilation/top-drugs-by-sales-in-2020-who-sold-the-blockbuster-drugs PharmaCompass (2021). PharmaCompass compilation of top drugs and pharma companies by sales in 2021. Retrieved from: https://www.pharmacompass.com/data-compilation/top-drugs-by-sales-in-2021-who-sold-the-blockbuster-drugs Prajapati, V., & Dureja, H. (2012). Product lifecycle management in pharmaceuticals. Journal of Medical Marketing, 12(3), 150-158. Prajapati, V., Tripathy, S., & Dureja, H. (2013). Product lifecycle management through patents and regulatory strategies. Journal of Medical Marketing, 13(3), 171-180. Qu, P., Zhang, J., Yao, C., & Zeng, W. (2016). Identifying long tail term from large?scale candidate pairs for big data?oriented patent analysis. Concurrency and Computation: Practice and Experience, 28(15), 4194-4208. Rusu, A., Kuokkanen, K., & Heier, A. (2011). Current trends in the pharmaceutical industry–A case study approach. European Journal of Pharmaceutical Sciences, 44(3), 437-440. Sampat, B. N., & Shadlen, K. C. (2015). TRIPS implementation and secondary pharmaceutical patenting in Brazil and India. Studies in Comparative International Development, 50(2), 228-257. Shibata, S., Uemura, R., & Suzuki, T. (2016). Comparative analysis between the top-selling drugs in the Japanese pharmaceutical market and those in the United States, the United Kingdom, France, and Germany. Therapeutic Innovation & Regulatory Science, 50(2), 221-227. Smith, R. B. (2011). Repositioned drugs: Integrating intellectual property and regulatory strategies. Drug Discovery Today: Therapeutic Strategies, 8(3-4), 131-137. Song, C. H., Han, J. W. (2016). Patent cliff and strategic switch: Exploring strategic design possibilities in the pharmaceutical industry. SpringerPlus, 5(1), 692-706. Son, K. B., Bae, S., & Lee, T. J. (2019). Does the patent linkage system prolong effective market exclusivity? Recent evidence from the Korea-US Free Trade Agreement in Korea. International Journal of Health Services, 49(2), 306-321. Son, K. B. (2021a). Market exclusivity of the originator drugs in South Korea: A retrospective cohort study. Frontiers in public health, 9, 264. Son, K. B. (2021b). Understanding long-listed pharmaceutical products without competition in South Korea: policy implications in managing generic entrants and pharmaceutical expenditures. Expert review of pharmacoeconomics & outcomes research, 1-8. Treasure, C. L., & Kesselheim, A. S. (2016). How patent troll legislation can increase timely access to generic drugs. JAMA Internal Medicine, 176(6), 729-730. U.S. Food and Drug Administration. (2017). The FDA's Drug Review Process: Ensuring Drugs Are Safe and Effective. Retrieved from: https://www.fda.gov/drugs/information-consumers-and-patients-drugs/fdas-drug-review-process-ensuring-drugs-are-safe-and-effective U.S. Food and Drug Administration. (2022). Approved Drug Products with Therapeutic Equivalence Evaluations | Orange Book. Retrieved from: https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book Vokinger, K. N., Kesselheim, A. S., Avorn, J., & Sarpatwari, A. (2017). Strategies that delay market entry of generic drugs. JAMA internal medicine, 177(11), 1665-1669. Wang, B., Liu, J., & Kesselheim, A. S. (2015). Variations in time of market exclusivity among top-selling prescription drugs in the United States. JAMA internal medicine, 175(4), 635-637. Wagner, S., & Wakeman, S. (2016). What do patent-based measures tell us about product commercialization? Evidence from the pharmaceutical industry. Research Policy, 45(5), 1091-1102. White, E. K. (2017). Killing U.S. slowly: Curing the epidemic rise of cancer drug prices. Food and drug law journal, 72(1), 189-224. Wittfoth, S. (2019). Measuring technological patent scope by semantic analysis of patent claims–An indicator for valuating patents. World Patent Information, 58, 101906. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/83354 | - |
| dc.description.abstract | 品牌藥在核准上市後開始經歷生命週期，當生命週期即將結束，會面臨的專利到期或學名藥競爭。次級專利是製藥公司為了保護品牌藥免於面臨專利到期後的龐大損失，為品牌藥申請之涵蓋藥物活性成分以外的外圍特徵的專利，是製藥公司的重要策略。本研究以年收十億美金以上的重磅炸彈藥為例，逐一查看2015年至2021年的重磅炸彈藥的次級專利資料並加以分類，將次級專利分為：新配方（New formulation）、新適應症（New indication）、相關化學結構 （Related chemical structures）、組合物（Composition）、其他（The others）五類型，以卡方獨立性檢定探討重磅炸彈藥生命週期中各類型次級專利的連結及差異，並進一步以製藥公司及藥物治療領域的角度切入探討。重磅炸彈藥傾向於研發期申請大量次級專利，新適應症次級專利為主要申請類型。重磅炸彈藥以抗腫瘤與抗感染為主，製藥公司專注於其優勢藥物治療領域。值得一提的是，製藥公司對於重磅炸彈藥與非重磅炸彈藥的專利申請態度相同。本研究亦針對製藥產業與學術領域中提出對藥物的次級專利策略建議。 | zh_TW |
| dc.description.abstract | Brand drugs go through life cycle after approval. When the life cycle is about to end, brand drugs will face patent expiration or generic drug competition. Secondary patents are patents covering peripheral features rather than active ingredient of drugs in order to protect brand drugs from huge losses after patent expiration. Secondary patenting is an important strategy for pharmaceutical companies. This study takes blockbuster drugs as example, examines and classifies every secondary patent of blockbuster drugs from 2015 to 2021, and divides secondary patents into five types: new formulation, new indication, related chemical structure, composition, and the others, discussing the connection and differences of secondary patents in blockbuster drugs’ life cycle by Chi-Squared Tests of Independence, and the perspective of pharmaceutical companies and therapeutic classification is also discussed. Blockbuster drugs tend to gain a large number of secondary patents during the R&D period, with new indication secondary patent as the main type. Blockbuster drugs are mainly for oncology and infectious diseases, and pharmaceutical companies focus on their dominant drug therapeutic classification. It is worth mentioning that pharmaceutical companies have the same attitude towards their blockbuster drugs as non-blockbuster drugs. This study also proposes drug secondary patenting strategies for pharmaceutical industry and academia. | en |
| dc.description.provenance | Made available in DSpace on 2023-03-19T21:05:26Z (GMT). No. of bitstreams: 1 U0001-2009202216593400.pdf: 2273025 bytes, checksum: 9c14773c35465ab7172ef1fc80e65856 (MD5) Previous issue date: 2022 | en |
| dc.description.tableofcontents | 誌謝 i 摘要 ii ABSTRACT ii 目錄 iii 圖目錄 v 表目錄 vi 第一章 緒論 1 第一節、研究背景 1 第二節、研究動機 4 第三節、研究目的 6 第四節、名詞解釋 8 第二章 文獻回顧 10 第一節、製藥產業與品牌藥的生命週期 10 第二節、品牌藥的次級專利連結 17 第三節、藥物與專利計量分析 24 第三章 研究方法 29 第一節、資料收集與整理 29 第二節、定義與分類 36 第三節、卡方獨立性檢定 41 第四節、藥物發明價值指標 44 第四章 研究結果 46 第一節、重磅炸彈藥在生命週期各階段的次級專利連結 46 第二節、製藥公司的重磅炸彈藥的次級專利布局 50 第三節、藥物治療領域的重磅炸彈藥的次級專利布局 63 第五章 結論與建議 73 第一節、結論 73 第二節、研究建議 79 第三節、研究限制 81 參考文獻： 82 附錄 88 | |
| dc.language.iso | zh-TW | |
| dc.subject | 次級專利 | zh_TW |
| dc.subject | 藥物治療領域 | zh_TW |
| dc.subject | 製藥公司 | zh_TW |
| dc.subject | 重磅炸彈藥 | zh_TW |
| dc.subject | 生命週期 | zh_TW |
| dc.subject | Secondary patents | en |
| dc.subject | Therapeutic classification | en |
| dc.subject | Pharmaceutical companies | en |
| dc.subject | Blockbuster drugs | en |
| dc.subject | Life cycle | en |
| dc.title | 從品牌藥的生命週期探討次級專利布局策略：以重磅炸彈藥為例 | zh_TW |
| dc.title | The secondary-patenting strategy during brand drugs’ life cycle: A study of Blockbuster drugs | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 110-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 薛招治(Chao-Chih Hsueh),董蕙茹(Huei-Ru Dong) | |
| dc.subject.keyword | 重磅炸彈藥,生命週期,次級專利,製藥公司,藥物治療領域, | zh_TW |
| dc.subject.keyword | Blockbuster drugs,Life cycle,Secondary patents,Pharmaceutical companies,Therapeutic classification, | en |
| dc.relation.page | 95 | |
| dc.identifier.doi | 10.6342/NTU202203661 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2022-09-23 | |
| dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
| dc.contributor.author-dept | 生物產業傳播暨發展學研究所 | zh_TW |
| 顯示於系所單位： | 生物產業傳播暨發展學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-2009202216593400.pdf 未授權公開取用 | 2.22 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。